33631-01-5

Basic information

• Product Name: 3-Amino-1-methylpyridin-2(1H)-one
• Synonyms: 3-Amino-1-methylpyridin-2(1H)-one;3-Amino-1-methylpyridin-2...;3-AMino-1-Methyl-2(1H)-pyridin-2-one;2(1H)-Pyridinone, 3-aMino-1-Methyl-;3-aMino-1-Methyl-1,2-dihydropyridin-2-one;3-amino-1-methyl-2(1H)-Pyridinone;3-Amino-1-methyl-pyridin-2-one;3-Amino-1-methylpyridin-2(1H)
• CAS NO: 33631-01-5
• Molecular Formula: C₆H₈N₂O
• Molecular Weight: 124.14052
• Mol File: 33631-01-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 296 °C at 760 mmHg
• Flash Point: 132.8 °C
• Appearance: /
• Density: 1.169 g/cm³
• Vapor Pressure: 0.00147mmHg at 25°C
• Refractive Index: 1.557
• Storage Temp.: 2-8°C(protect from light)
• PKA: 3.54±0.20(Predicted)
• CAS DataBase Reference: 3-Amino-1-methylpyridin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-1-methylpyridin-2(1H)-one(33631-01-5)
• EPA Substance Registry System: 3-Amino-1-methylpyridin-2(1H)-one(33631-01-5)

Safety Data

• Hazardous Substances Data: 33631-01-5(Hazardous Substances Data)

Usage

General Description

3-Amino-1-methylpyridin-2(1H)-one, also known as AMPO, is a chemical compound with the molecular formula C6H8N2O. It is a heterocyclic compound with a pyridine ring and an amino group, as well as a carbonyl group. AMPO has potential applications in organic synthesis and pharmaceutical research, and it is often used as a building block in the production of other chemical compounds. Its specific properties and uses make it a valuable tool in the development of new drugs and materials with diverse applications.

InChI:InChI=1/C6H8N2O/c1-8-4-2-3-5(7)6(8)9/h2-4H,7H2,1H3

Upstream product

• 32896-91-6 1-methyl-3-nitropyridin-2(1H)-one 
• 6332-56-5 3-nitropyridone 

Relevant articles and documents

Pyrrolopyrimidine derivative as well as preparation method and application thereof

The invention belongs to the technical field of medicines, and provides a compound shown as a general formula (I), geometric isomers or pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and preparation methods thereof, wherein A, B and R1 are described in the claims and the specification. The compound and the geometric isomer thereof or the pharmaceutically acceptable salt, hydrate, solvate, prodrug or pharmaceutical composition thereof have the activity as a protein kinase inhibitor, especially an FAK kinase inhibitor.

Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents

A series of 7H-pyrrolo[2,3-d]pyrimidine derivatives possessing a dimethylphosphine oxide moiety were designed, synthesized and evaluated as novel Focal adhesion kinase (FAK) inhibitors. Most compounds potently suppressed the enzymatic activities of FAK, with IC50 values in the 10?8–10?9 M range, and potently inhibited the proliferation of breast (MDA-MB-231) and lung (A549) cancer cell lines. The representative compound 25b exhibited potent enzyme inhibition (IC50 = 5.4 nM) and good selectivity when tested on a panel of 26 kinases. 25b exhibited antiproliferative activity against A549 cells (IC50 = 3.2 μM) and relatively less cytotoxicity to a normal human cell line HK2. Compound 25b also induced apoptosis and suppressed the migration of A549 cells in a concentration-dependent manner. Further profiling of compound 25b revealed it had good metabolic stability in mouse, rat and human liver microsomes in vitro and showed weak inhibitory activity against various subtypes of human cytochrome P450. The docking study of compound 25b was performed to elucidate its possible binding modes and to provide a structural basis for further structure-guided design of FAK inhibitors.

Discovery of new nanomolar inhibitors of GPa: Extension of 2-oxo-1,2-dihydropyridinyl-3-yl amide-based GPa inhibitors

Glycogen Phosphorylase (GP) is a functionally active dimeric enzyme, which is a target for inhibition of the conversion of glycogen to glucose-1-phosphate. In this study we report the design and synthesis of 14 new pyridone derivatives, and seek to extend the SAR analysis of these compounds. The SAR revealed the minor influence of the amide group, importance of the pyridone ring both spatially around the pyridine ring and for possible π-stacking, and confirmed a preference for inclusion of 3,4-dichlorobenzyl moieties, as bookends to the pyridone scaffold. Upon exploring a dimer strategy as part of the SAR analysis, the first extended 2-oxo-dihydropyridinyl-3-yl amide nanomolar based inhibitors of GPa (IC50?=?230 and 260?nM) were identified.